Table 1.
Local and general reaction following 1st and 2nd dose of mRNA-1273 SARS-CoV-2 Vaccine
| After 1st vaccine dose |
After 2nd vaccine dose |
|
|---|---|---|
| n | 454 | 454 |
| Headache, n (%) any | 12 (2.6) | 33 (7.2) |
| Mild | 10 (2.2) | 27 (5.9) |
| Moderate | 1 (0.2) | 5 (1.1) |
| Severe | 1 (0.2) | 1 (0.2) |
| Grade 4 | 0 | 0 |
| Diarrhea, n (%) | 5 (1.1) | 2 (0.4) |
| Mild | 3 (0.7) | 1 (0.2) |
| Moderate | 2 (0.4) | 1 (0.2) |
| Severe | 0 | 0 |
| Grade 4 | 0 | 0 |
| Vomiting, n (%) | 5 (1.1) | 2 (0.4) |
| Mild | 3 (0.7) | 1 (0.2) |
| Moderate | 2 (0.4) | 1 (0.2) |
| Severe | 0 | 0 |
| Grade 4 | 0 | 0 |
| Local reactions, n (%) | 265 (58.4) | 157 (34.6) |
| Mild | 256 (56.4) | 148 (32.6) |
| Moderate | 9 (2.0) | 9 (2.0) |
| Severe | 0 | 0 |
| Grade 4 | 0 | 0 |
| Fever 37–37.9 °C, n (%) | 5 (1.1) | 76 (16.7) |
| Mild | 4 (0.9) | 76 (16.7) |
| Moderate | 1 (0.2) | 0 |
| Severe | 0 | 0 |
| Grade 4 | 0 | 0 |
| Fever > 38 °C, n (%) | 0 | 56 (12.3) |
| Mild | 0 | 55 (12.1) |
| Moderate | 0 | 1 (0.2) |
| Severe | 0 | 0 |
| Grade 4 | 0 | 0 |
| Lymphadenopathy, n (%) | 5 (1.1) | 1 (0.2) |
| Mild | 4 (0.9) | 1 (0.2) |
| Moderate | 1 (0.2) | 0 |
| Severe | 0 | 0 |
| Grade 4 | 0 | 0 |
| New or worsening Myalgia or Joint pain, n (%) | 22 (4.8) | 72 (15.8) |
| Mild | 19 (4.2) | 65 (14.3) |
| Moderate | 3 (0.6) | 7 (1.5) |
| Severe | 0 | 0 |
| Grade 4 | 0 | 0 |
| Perioral paresthesia, n (%) | 1 (0.2) | 0 |
| Mild | 1 (0.2) | 0 |
| Moderate | 0 | 0 |
| Severe | 0 | 0 |
| Grade 4 | 0 | 0 |
| Fatigue, n (%) | 51 (11.2) | 69 (15.2) |
| Mild | 49 (10.8) | 62 (13.7) |
| Moderate | 2 (0.4) | 7 (1.5) |
| Severe | 0 | 0 |
| Grade 4 | 0 | 0 |
| Fainting, n (%) | 1 (0.2) | 1 (0.2) |
| Mild | 1 (0.2) | 1 (0.2) |
| Moderate | 0 | 0 |
| Severe | 0 | 0 |
| Grade 4 | 0 | 0 |
| Tachycardia, n (%) | 2 (0.4) | 1 (0.2) |
| Mild | 2 (0.4) | 1 (0.2) |
| Moderate | 0 | 0 |
| Severe | 0 | 0 |
| Grade 4 | 0 | 0 |
| Anaphylactic reaction, n (%) | 0 | 0 |
| Urticaria, n (%) | 0 | 0 |
| Other (%) | 18 (4.2) | 69 (15.2) |